Subsidiary of Shenzhen Kangtai Biological Products (300601.SZ) received the summary report of Phase I/III clinical trials of adsorbed tetanus vaccine.

03/03/2025

GMT Eight

Shenzhen Kangtai Biological Products (300601.SZ) announced that its wholly-owned subsidiary Beijing Minhai Biological Technology Co., Ltd. ("Minhai Biological") recently received the summary report of the phase I/III clinical trial of its adsorbed tetanus vaccine. The clinical research stage of Minhai Biological's developed adsorbed tetanus vaccine has been successfully completed. The research results show that the adsorbed tetanus vaccine developed by Minhai Biological has good safety and immunogenicity when used for adult immunization. The acquisition of the summary report of the phase I/III clinical trial of the adsorbed tetanus vaccine indicates that it meets the necessary conditions for production application.

Hengdian Group Tospo Lighting (603303.SH) has repurchased a total of 9.2855 million shares, costing 109 million yuan.

Anhui Anli Material Technology (300218.SZ): Water-based solvent-free polyurethane composite material key technology selected for the first batch of advanced and applicable technologies list by the Ministry of Industry and Information Technology.

Contact: contact@gmteight.com

Subsidiary of Shenzhen Kangtai Biological Products (300601.SZ) received the summary report of Phase I/III clinical trials of adsorbed tetanus vaccine.

RECOMMEND

HK Stock Market Move | KINGKEY FIN INT (01468) opened nearly 5% higher and is considering setting up investment opportunities and services involving cryptocurrency license regulation.

HK Stock Market Move | ALPHAMAB-B (09966) surged more than 11% at the opening, expected to achieve annual profit for the first time with a profit of no less than 1.5 billion yuan.

HK Stock Market Move | XD INC (02400) opened more than 11% higher after the profit celebration, with an expected net profit of up to 940 million yuan last year, turning losses into profits year-on-year.